These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 2122647)
21. [Treatment of pharmacotoxic psychoses with clopenthixol in patients with Parkinson's disease (author's transl)]. Danielczyk W Wien Klin Wochenschr; 1981 Aug; 93(15):500-1. PubMed ID: 7303692 [TBL] [Abstract][Full Text] [Related]
22. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Melamed E; Zoldan J; Friedberg G; Ziv I; Weizmann A Adv Neurol; 1996; 69():545-50. PubMed ID: 8615179 [No Abstract] [Full Text] [Related]
23. Therapeutic dilemma: psychosis and Parkinson's disease. Damecour CL; Turcotte JR Can J Psychiatry; 1995 Dec; 40(10):640-1. PubMed ID: 8681265 [No Abstract] [Full Text] [Related]
24. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Greene P; Cote L; Fahn S Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214 [No Abstract] [Full Text] [Related]
25. Managing psychosis in patients with Parkinson's disease. Cummings JL N Engl J Med; 1999 Mar; 340(10):801-3. PubMed ID: 10072418 [No Abstract] [Full Text] [Related]
26. Parkinson's disease in 1984: an update. Lang AE; Blair RD Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779 [TBL] [Abstract][Full Text] [Related]
27. Drug treatment of Parkinson's disease. Callaghan N Ir Med J; 1983 Aug; 76(8):364-6. PubMed ID: 6618850 [No Abstract] [Full Text] [Related]
28. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)]. Ringwald E; Hirt D; Markstein R; Vigouret JM Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089 [No Abstract] [Full Text] [Related]
29. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062 [TBL] [Abstract][Full Text] [Related]
31. [Drug treatment of Parkinson's disease]. Jansen EN Ned Tijdschr Geneeskd; 1986 May; 130(20):897-9. PubMed ID: 3724862 [No Abstract] [Full Text] [Related]
32. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Tison F; Wiart L; Guatterie M; Fouillet N; Lozano V; Henry P; Barat M Mov Disord; 1996 Nov; 11(6):729-32. PubMed ID: 8914103 [TBL] [Abstract][Full Text] [Related]
33. What to do when Sinemet fails: Part one. Klawans HL Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692 [No Abstract] [Full Text] [Related]
34. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Klein C; Prokhorov T; Miniovich A; Dobronevsky E; Rabey JM Clin Neuropharmacol; 2006; 29(4):215-9. PubMed ID: 16855423 [TBL] [Abstract][Full Text] [Related]
35. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. Rich SS; Friedman JH; Ott BR J Clin Psychiatry; 1995 Dec; 56(12):556-9. PubMed ID: 8530331 [TBL] [Abstract][Full Text] [Related]
36. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Reddy S; Factor SA; Molho ES; Feustel PJ Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856 [TBL] [Abstract][Full Text] [Related]
37. [Value of clozapine in treatment of psychotic disorder in Parkinson disease]. Abbar M; Courtet P; Castelnau D Encephale; 1996; 22(1):53-63. PubMed ID: 8681876 [TBL] [Abstract][Full Text] [Related]
38. [Between Scylla and Charybdis: drug-induced psychosis in patients with Parkinson disease]. Kuiper MA; Zwaan WA; Wolters EC Ned Tijdschr Geneeskd; 1994 Jul; 138(27):1353-7. PubMed ID: 8035892 [No Abstract] [Full Text] [Related]